Browse Negotiations Image Banner

Banner Text Velit velaliquam, ultricies eros dolore magna in in doming ullamco sint. Sint doming dignissim in quis pariatur consequat urna eu providerent. Sint dolore ea urna velit doming ea pulvinar.

General Callout

Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.

Accordion

Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.

Heading 1

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Heading 2

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Related content

Dolor commodo suscipit adipiscing suscipit, elit dolore velit. Amet tempuribud velit pariatur ullamco exercitation esse dolore sint velaliquam adipiscing eu pulvinar doming sunt, dignissim velit voluptate ex suscipit sunt ex, duis dignissim nunc tempuribud laboris commodo velit ut. Velit in harmud quis voluptate esse nulla.

Shop Now!

Laboris quis consectetur sed eros velit tempuribud suscipit magna ea consequat laboris. Elit adipiscing quis sunt duis magna nulla velit amet elit ex providerent consectetur tempuribud amet ex commodo urna, magna adipiscing elit sed duis nisi pulvinar, doming pariatur velaliquam quis providerent fugiat ea aliquip sit ut nisi sunt pulvinar eu velit.

grey rec centre

Call to action

Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate

Primary Button Secondary Button

Search by drug, manufacturer, or indication

Displaying 741 - 750 of 1165

Januvia (sitagliptin phosphate)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated March 10, 2020

Xtandi (enzalutamide)

Status:

Concluded with an LOI

Manufacturer:

Astellas Pharma Inc.

Indication:

Non-metastatic Castration-resistant prostate cancer

Last updated February 26, 2020

Bosulif (bosutinib)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

Chronic Myeloid Leukemia

Last updated February 19, 2020

Kuvan (sapropterin dihydrochloride)

Status:

Concluded with an LOI

Manufacturer:

BioMarin Pharmaceutical Inc.

Indication:

Phenylketonuria

Last updated February 13, 2020

Truxima (rituximab)

Status:

Concluded with an LOI

Manufacturer:

Teva Canada Ltd.

Indication:

Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma

Last updated February 12, 2020

Vizimpro (dacomitinib)

Status:

Concluded without agreement

Manufacturer:

Pfizer Canada ULC

Indication:

Non-Squamous Non-Small Cell Lung Cancer

Last updated February 11, 2020

Nerlynx (neratinib)

Status:

Negotiations were not pursued

Manufacturer:

Knight Therapeutics Inc.

Indication:

Hormone Receptor-Positive Breast Cancer

Last updated February 4, 2020

Emerade (epinephrine bitartrate)

Status:

Concluded with an LOI

Manufacturer:

Bausch Health, Canada Inc.

Indication:

For the emergency treatment of severe acute allergic reactions (anaphylaxis).

Last updated February 4, 2020

Brineura (cerliponase alfa)

Status:

Concluded with an LOI

Manufacturer:

BioMarin Pharmaceutical Inc.

Indication:

Neuronal Ceroid Lipofuscinosis Type 2

Last updated January 22, 2020

Folotyn (pralatrexate)

Status:

Concluded with an LOI

Manufacturer:

Servier Canada Inc.

Indication:

Peripheral T-cell Lymphoma (PTCL)

Last updated January 10, 2020